Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;35(12):12427-34.
doi: 10.1007/s13277-014-2560-2. Epub 2014 Sep 9.

MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF

Affiliations
Free article

MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF

Li-Qiang Wei et al. Tumour Biol. 2014 Dec.
Free article

Abstract

MicroRNAs (miRNAs) play critical roles in the development and progression of ovarian cancer. We found that miR-212 was significantly downregulated in serum and tissues from epithelial ovarian cancer (EOC) patients. Overexpression of miR-212 in ovarian cancer cells inhibited cell proliferation, migration, and invasion. Luciferase reporter assay confirmed HBEGF as a direct target of miR-212. Overexpression of miR-212 decreased HBEGF expression at both the protein and messenger RNA (mRNA) levels. Knockdown of HBEGF expression in SKOV3 cell line significantly inhibited cell growth, migration, and invasion. HBEGF mRNA level was upregulated in EOC tissues and inversely correlated with miR-212 expression in tissues. Upregulation of HBEGF could attenuate the effect induced by miR-212. These findings indicate that miR-212 displays a tumor-suppressive effect in human ovarian cancer. And miR-212 suppresses cell proliferation, migration, and invasion by targeting the HBEGF transcript, highlighting the therapeutic potential of miR-212 and HBEGF in epithelial ovarian cancer treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. EMBO J. 1994 May 15;13(10):2322-30 - PubMed
    1. Mol Cell Pharmacol. 2011;3(3):83-92 - PubMed
    1. Oncol Rep. 2012 Apr;27(4):954-8 - PubMed
    1. Gastroenterology. 2013 Aug;145(2):426-36.e1-6 - PubMed
    1. J Cell Biol. 1995 Mar;128(5):929-38 - PubMed

Publication types

MeSH terms